Clinical Trials Logo

Nephrotoxicity clinical trials

View clinical trials related to Nephrotoxicity.

Filter by:

NCT ID: NCT06360666 Enrolling by invitation - Mortality Clinical Trials

Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia

NEURAX
Start date: October 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about postoperative mortality and postoperative length of stay outcomes after abdominal laparoscopic major surgery. The main question it aims to answer is: Does general anesthesia lower complications compared to loco-regional anesthesia (keeping the patient spontaneously breathing and sedated) in laparoscopic abdominal major surgery? Participants are followed for neurological sequelae for 90 days following surgery

NCT ID: NCT06153147 Recruiting - Hypertension Clinical Trials

KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)

KINDEST-CCS
Start date: January 5, 2024
Phase:
Study type: Observational

Background: Childhood cancer survivors (CCS) are at elevated risk of chronic health conditions. Chemotherapies can cause recurrent acute kidney injury which may progress to kidney fibrosis, chronic kidney disease (CKD) or hypertension (HTN). CCS surviving to adulthood are at ≥3 times the risk (vs. non-CCS) for CKD, HTN and lower quality of life. However, the timing of CKD and HTN onset in CCS completing cancer therapy in childhood remains unclear. Guidelines provide recommendations on managing post-cancer therapy effects in CCS, but they lack specificity on kidney testing content, frequency and complications. This discord is largely due to knowledge gaps on which CCS develop CKD or HTN after cancer therapy, when outcomes occur and their severity. Existing work has shown in select patients, CKD and HTN in CCS likely begins in the first 5 years post-cancer therapy and that the burden is significant. With robust data on CKD and HTN, international CCS follow-up guidelines can be optimized to include detailed and actionable recommendations on kidney and blood pressure monitoring and treatment.

NCT ID: NCT05673824 Recruiting - Nephrotoxicity Clinical Trials

Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.

Start date: February 7, 2023
Phase: Phase 4
Study type: Interventional

This is a prospective, single-arm, single-center, exploratory study. The purpose of this study is to explore the effect of Huaier Granule on nephrotoxicity associated with anti-angiogenesis targeted therapy for advanced hepatobiliary malignancies.

NCT ID: NCT04354467 Completed - Acute Kidney Injury Clinical Trials

Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU

Start date: January 28, 2019
Phase:
Study type: Observational

Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at UAB/Children's of Alabama Hospital, NTMx exposure was found to be potentially modifiable and the associated AKI is an avoidable adverse safety event. Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI. The hypothesis of this NINJA NGAL study is that urine NGAL is highly sensitive to detect NTMx-associated AKI. UAB/Children's of Alabama is bringing urine NGAL measurement to the infants in the NICU to detect NTMX-associated AKI.

NCT ID: NCT03817970 Recruiting - Nephrotoxicity Clinical Trials

Cisplatin Disposition and Kidney Injury

Start date: November 15, 2019
Phase: Phase 3
Study type: Interventional

This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.

NCT ID: NCT03527160 Completed - Acute Kidney Injury Clinical Trials

Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications

NINJA NGAL
Start date: April 23, 2018
Phase:
Study type: Observational

Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at Cincinnati Children's Medical Center, NTMx exposure was found to be potentially modifiable and the associated AKI is an avoidable adverse safety event. Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI. The hypotheses of this NINJA NGAL study are that (1) urine NGAL is highly sensitive to detect NTMx-associated AKI, and (2) Bedside test of urine from high risk NTMx-exposed patients are adequate and reliable compared to urine NGAL measured from the clinical platform.

NCT ID: NCT03480971 Recruiting - Mucositis Clinical Trials

Treatment of Radiation and Cisplatin Induced Toxicities With Tempol

Start date: May 13, 2019
Phase: Phase 2
Study type: Interventional

A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.

NCT ID: NCT03438214 Not yet recruiting - Sepsis Clinical Trials

Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients

ETERNITY
Start date: April 28, 2018
Phase: Phase 4
Study type: Interventional

This is a randomized, controlled multicenter clinical trial. The purpose of this study is to compare the continuous infusion of vancomycin with intermittent infusion regarding the effectiveness to reach the target serum level and the relationship between infusion type and nephrotoxicity in critically ill patients.

NCT ID: NCT02528448 Recruiting - Nephrotoxicity Clinical Trials

0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis

KIPA
Start date: March 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if chloride is nephrotoxic using 0,9% saline versus Plasma-Lytein in patients having primary hip replacement surgery. The outcome is found measuring bio markers, vasoactive hormones and salt regulation. And to measure syndecan as a marker for glycocalyx degradation.

NCT ID: NCT02103855 Completed - Nephrotoxicity Clinical Trials

Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients

Start date: June 2014
Phase: Phase 4
Study type: Interventional

Kidney damage is a major complication of current antirejection medicines used in transplantation. An increasing number of brittle diabetics are successfully receiving a pancreas transplant. One of the challenges following pancreas transplant is that a patient can develop kidney damage from one of their antirejection medicines, tacrolimus. The objective of this study is to substitute a new antirejection medicine which does not cause kidney damage, belatacept for tacrolimus in patients that have developed signs of tacrolimus related kidney damage to slow the progression of kidney disease.